Cyclacel Pharmaceuticals, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Cyclacel Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2010 to Q2 2024.
  • Cyclacel Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was -$412K, a 29.7% increase year-over-year.
  • Cyclacel Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was -$2.86M, a 36.5% increase year-over-year.
  • Cyclacel Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was -$3M, a 36.5% increase from 2022.
  • Cyclacel Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was -$4.72M, a 26.5% decline from 2021.
  • Cyclacel Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was -$3.73M, a 202% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$2.86M -$412K +$174K +29.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$3.03M -$1.35M -$34K -2.58% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$3M -$422K +$1.16M +73.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$4.16M -$668K +$346K +34.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-29
Q2 2023 -$4.5M -$586K +$398K +40.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$4.9M -$1.32M -$182K -16% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$4.72M -$1.58M +$1.43M +47.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$6.15M -$1.01M -$1.95M -209% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-29
Q2 2022 -$4.2M -$984K -$20K -2.08% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$4.18M -$1.14M -$451K -65.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$3.73M -$3.01M -$2.63M -694% Oct 1, 2021 Dec 31, 2021 10-K/A 2023-11-29
Q3 2021 -$1.1M $934K +$1.22M Jul 1, 2021 Sep 30, 2021 10-K/A 2023-11-29
Q2 2021 -$2.31M -$964K -$678K -237% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$1.63M -$687K -$397K -137% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$1.24M -$379K +$69K +15.4% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 -$1.31M -$281K -$8K -2.93% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$1.3M -$286K +$21K +6.84% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$1.32M -$290K -$22K -8.21% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$1.3M -$448K -$96K -27.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$1.2M -$273K +$28K +9.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$1.23M -$307K +$195K +38.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$1.42M -$268K -$86K -47.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$1.34M -$352K -$152K -76% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-05
Q3 2018 -$1.19M -$301K -$82K -37.4% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 -$1.1M -$502K -$234K -87.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 -$869K -$182K +$124K +40.5% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q4 2017 -$993K -$200K +$210K +51.2% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-28
Q3 2017 -$1.2M -$219K +$235K +51.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$1.44M -$268K +$358K +57.2% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 -$1.8M -$306K +$187K +37.9% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 -$1.98M -$410K +$88K +17.7% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-30
Q3 2016 -$2.07M -$454K +$24K +5.02% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 -$2.1M -$626K -$221K -54.6% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
Q1 2016 -$1.87M -$493K +$270K +35.4% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
Q4 2015 -$2.14M -$498K +$610K +55.1% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-31
Q3 2015 -$2.75M -$478K +$272K +36.3% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 -$3.03M -$405K +$411K +50.4% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-11
Q1 2015 -$3.44M -$763K -$194K -34.1% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-13
Q4 2014 -$3.24M -$1.11M -$656K -145% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-29
Q3 2014 -$2.59M -$750K -$20K -2.74% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 -$2.57M -$816K -$586K -255% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-12
Q1 2014 -$1.98M -$569K -$311K -121% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-12
Q4 2013 -$1.67M -$452K +$185K +29% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-31
Q3 2013 -$1.86M -$730K -$311K -74.2% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-12
Q2 2013 -$1.54M -$230K -$103K -81.1% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-12
Q1 2013 -$1.44M -$258K -$90K -53.6% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-13
Q4 2012 -$1.35M -$637K -$515K -422% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-26
Q3 2012 -$836K -$419K -$293K -233% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-14
Q2 2012 -$543K -$127K -$1K -0.79% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-14
Q1 2012 -$542K -$168K +$23K +12% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-13
Q4 2011 -$565K -$122K Oct 1, 2011 Dec 31, 2011 10-K 2014-03-26
Q3 2011 -$126K +$17K +11.9% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-16
Q2 2011 -$126K +$104K +45.2% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-14
Q1 2011 -$191K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-15
Q3 2010 -$143K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
Q2 2010 -$230K Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.